True Wealth Design’s Travere Therapeutics TVTX Stock Holding History

True Wealth Design’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.71K	Buy	63 +1	+2%	+$61	﹤0.01%	1453
2026 Q2	$3.52K	Hold	62	–	–	﹤0.01%	1470
2026 Q1	$1.84K	Sell	62 -13	-17%	-$389	﹤0.01%	1583
2025 Q4	$2.87K	Buy	75 +13	+21%	+$423	﹤0.01%	1311
2025 Q3	$1.48K	Buy	+62	New	+$1.17K	﹤0.01%	1599
2025 Q2	–	Sell	-288	Closed	-$5.16K	–	2826
2025 Q1	$5.16K	Hold	288	–	–	﹤0.01%	679
2024 Q4	$5.02K	Buy	288 +60	+26%	+$1.06K	﹤0.01%	532
2024 Q3	$3.19K	Buy	+228	New	+$2.38K	﹤0.01%	674

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

True Wealth Design's TVTX Position: Q3 2026 in Review

True Wealth Design increased its Travere Therapeutics (TVTX) stake by 1.6% in Q3 2026, buying an estimated $61 and bringing the position to 63 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1453.

True Wealth Design first reported a position in TVTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.16K in Q1 2025. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

True Wealth Design held 63 shares of Travere Therapeutics worth $3.71K as of Q3 2026.
True Wealth Design bought 1 Travere Therapeutics share in Q3 2026, an estimated $61.
Travere Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1453 holding.
True Wealth Design first reported a position in Travere Therapeutics in Q3 2024 and has held it in 8 quarters since.
True Wealth Design's Travere Therapeutics position peaked at $5.16K in Q1 2025.
158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.